Further details on Endo: per Morningstar.com, "ENDP is engaged in the research, development, sales & marketing of branded & generic prescription drugs used for the treatment and management of pain."
Latest quarter results: Reported 7/24/03 by PRNewswire on NYTimes on the Web: Net sales for the second quarter of 2003 increased 41% to $152.0 million from $107.9 million for the second quarter of 2002. Net income for the second quarter of 2003 increased 105% to $45.2 million from $22.0 million in the comparable quarter of 2002. Diluted earnings per share were $.34 vs $.22 last year. (And now you can see why I liked this stock enough to purchase it!)
Morningstar trends: $108 million in revenue in 1998, $139 million in 1999, $197 million in 2000, $252 million in 2001 and $399 million in 2002, $484 million in the trailing twelve months.
Free cash flow: (check out these excellent results!) $34 million in 2000, $74 million in 2001, $107 million in 2002 and $142 million in the trailing twelve months.
Balance sheet: $96.5 million in cash and $221.9 million in other current assets vs $149.6 million in current liabilities and $7.8 million in long-term liabilities. (also very pretty!)
Other stats, per Yahoo.com: Market cap of 2.77 billion, p/e ratio a bit steep at 39.94, peg nice at 0.89, price/sales high at 4.88.
There are 131.76 million shares outstanding but only 30.30 million float.
I liked this stock when I first looked at it and I still like it. You can see why.
I purchased some shares already today....use your own judgment in deciding about whether they are a good idea! Regards again!